Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775573 | 0.93 | TAAR1 (0.56) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL25821224 | 0.90 | SMN1; SMN2 (0.53) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL104467 | 0.89 | TAAR1 (0.74) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL14199081 | 0.85 | TAAR1 (0.56) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL22885190 | 0.85 | TAAR1 (0.81) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL3841679 | 0.85 | TAAR1 (0.81) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL98038 | 0.85 | TAAR1 (0.56) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL19969484 | 0.85 | TAAR1 (0.56) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL18132989 | 0.82 | CYP3A4 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL2780037 | 0.82 | TAAR1 (0.82) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239821-A1 | N-ACYL FOSMIDOMYCIN PRODRUG ANALOGS AS NOVEL ANTIINFECTIVE AGENTS | THE GEORGE WASHINGTON UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023192669-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | DDT, CYP3A5, CYP4B1 | TAAR1 2699/4885SLC6A4 2047/4885SLC6A2 2991/4885 |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | TAAR1 4276/4885SLC6A4 794/4885SLC6A2 4435/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | TAAR1 195/4885SLC6A4 3148/4885SLC6A2 4544/4885 |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | TAAR1 3135/4885SLC6A4 2799/4885SLC6A2 3988/4885 |
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | TAAR1 359/4885SLC6A4 8/4885SLC6A2 164/4885 |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | TAAR1 2735/4885SLC6A4 16/4885SLC6A2 17/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | TAAR1 3457/4885SLC6A4 4206/4885SLC6A2 4176/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | TAAR1 1381/4885SLC6A4 419/4885SLC6A2 1287/4885 |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | TAAR1 2157/4885SLC6A4 4365/4885SLC6A2 4229/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | TAAR1 2182/4885SLC6A4 2163/4885SLC6A2 1587/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | TAAR1 3568/4885SLC6A4 3163/4885SLC6A2 3617/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | TAAR1 3108/4885SLC6A4 2429/4885SLC6A2 2911/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TAAR1 4581/4885SLC6A4 3048/4885SLC6A2 4018/4885 |
| US-20240239821-A1 | N-ACYL FOSMIDOMYCIN PRODRUG ANALOGS AS NOVEL ANTIINFECTIVE AGENTS | PSPH, PGLS, DNPEP | TAAR1 4702/4885SLC6A4 3616/4885SLC6A2 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.